Intracoronary diltiazem for microvascular spasm after interventional therapy

In summary, we found that no-reflow occurred in 4% of our patients who had undergone interventional procedures during a 5-month period, and were more common in patients with vein grafts or in those who had newer interventional devices. Intracoronary diltiazem led to prompt improvement in coronary blood flow in most patients and was well tolerated.